Skip to main content
. 2019 Feb 12;120(5):547–554. doi: 10.1038/s41416-019-0398-5

Fig. 4.

Fig. 4

Subgroup analyses for overall and relapse-free survival. HR, hazard ratio; 95% CI, 95% confidence interval; SqCC, squamous cell carcinoma; Non-SqCC, non-squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; Group 1 CD8-positive/PD-L1-negative, Group 2 CD8/PD-L1: positive/positive, negative/negative, or negative/positive